TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has facial acne vulgaris with:~  * 20 to 50 inflammatory lesions (papules, pustules, and nodules)~ * 25 to 100 noninflammatory lesions (open and closed comedones)~ * No more than 2 nodules on the face~ * IGA score of moderate (3) to severe (4)~* Willing to use only the supplied non-medicated cleanser (Cetaphil Gentle Skin Cleanser) and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study~Exclusion Criteria:~* Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne) or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations~* Sunburn on the face

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX-101, 4% minocycline foam (Type: EXPERIMENTAL): FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
- Vehicle Foam (Type: PLACEBO_COMPARATOR): Vehicle foam applied topically once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy infants in their first year of life and born at or after 35 weeks 0 days GA~* Infants who are entering their first RSV season at the time of screening~Key Exclusion Criteria:~* Meets national or other local criteria to receive commercial palivizumab~* Any fever (≥ 100.4°F \[≥ 38.0°C\], regardless of route) or acute illness within 7 days prior to randomization~* Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection~* Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 1 Year
- Healthy Volunteers: t

Study Arms:
- MEDI8897 (Type: EXPERIMENTAL): Anti-RSV monoclonal antibody with an extended half-life
- Placebo (Type: PLACEBO_COMPARATOR): Commercially available 0.9% (w/v) saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with proven iron deficiency anaemia on World Health Organisation (WHO)criteria Patients aged 13 - 18 will be considered adolescents, and aged \>18 as adults.~Exclusion Criteria:~Anaemia caused by B12 or folate deficiency, or secondary to drugs used to treat IBD; haemoglobinopathies or myelodysplasia; severe cardiopulmonary, hepatic or renal disease; severe cardiopulmonary, hepatic or renal disease; pregnancy and breast feeding females.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ferrous sulphate (Type: EXPERIMENTAL): Ferrous sulphate 200mg twice daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hypercholesterolemia (LDL-C ≥ 100 mg/dL)~* At high risk of CHD~* On stable, maximally tolerated statin therapy for 8 weeks~* On stable, low fat diet for 12 weeks~* Stable weight for 6 weeks~Exclusion Criteria:~* Significant health problems in the recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, hypertension, liver disease, cancer, type I diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once a week for 26 weeks.
- Mipomersen (Type: EXPERIMENTAL): Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maribavir for Prevention of CMV After Stem Cell Transplants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Allogeneic stem cell transplant recipient~* Recipient CMV seropositive~* Have transplant engraftment~* Able to swallow tablets~Exclusion Criteria:~* CMV organ disease~* HIV infection~* Use of other anti-CMV therapy post-transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Maribavir (100 mg twice daily) (Type: EXPERIMENTAL): None
- Maribavir (400 mg twice daily) (Type: EXPERIMENTAL): None
- Maribavir (400 mg once daily) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenomic Evaluation of Antihypertensive Responses 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* An average seated home diastolic blood pressure (DBP) \> 85 mmHg and \< 110 mmHg and home systolic blood pressure (SBP) \< 180 mmHg.~* Subjects must also have an average seated (\> 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP \< 180 mmHg~Exclusion Criteria:~* Secondary forms of hypertension (HTN) (including sleep apnea)~* Isolated systolic HTN~* Other diseases requiring treatment with BP lowering medications~* Heart rate \< 55 beats/min (for metoprolol only)~* Known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease, including stroke and TIA)~* Diabetes mellitus (Type 1 or 2)~* Renal insufficiency (serum creatinine \> 1.5 in men or 1.4 in women)~* Primary renal disease~* Pregnancy or lactation~* Liver enzymes \> 2.5 upper limits of normal~* Current treatment with NSAIDS, cyclooxygenase-2 (COX2) inhibitors, oral contraceptives or estrogen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metoprolol + Chlorthalidone (Type: EXPERIMENTAL): Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additional weeks if blood pressure (BP) \> 120/70 mmHg. BP measures were again recorded. Participants entered a washout where metoprolol was titrated, then discontinued, and the patient's hypertension was re-established. After another set of identical baseline labs, study participants were initiated on chlorthalidone 25 mg four days per week (Monday, Wednesday, Thursday, Saturday) 15 mg daily for two weeks, followed by 25 mg daily for an additional six weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes mellitus~* Has moderate or severe renal insufficiency~Exclusion Criteria:~* Has type 1 diabetes mellitus or a history of ketoacidosis~* Is on a new weight loss program~* Has active liver disease~* Is on dialysis or is likely to need dialysis during the study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin + Placebo for Glipizide
- Glipizide (Type: ACTIVE_COMPARATOR): Glipizide + Placebo for Sitagliptin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects who voluntarily sign the informed consent.~* Subject has successfully completed one of the three ABT-335, rosuvastatin, simvastatin and atorvastatin combination therapy studies.~Exclusion Criteria:~* Subject is using or will use investigational medications, except as approved by Abbott.~* Subject has prematurely discontinued his/her initial therapy one of the prior ABT-335, rosuvastatin, simvastatin and atorvastatin calcium combination therapy studies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): 20 mg drug and ABT-335
- B (Type: ACTIVE_COMPARATOR): 40 mg drug and ABT 335
- C (Type: ACTIVE_COMPARATOR): 40 mg drug and ABT-335

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 40~* Major surgery undergone\*~* High risk of postoperative VTE according to a National guideline\*\*~* 11+ Caprini scores~* Informed consent is given~Exclusion Criteria:~* Acute deep vein thrombosis (DVT) at baseline~* Performed inferior vena cava (IVC) plication or implanted IVC filter~* Regular preoperative anticoagulation~* Postoperative anticoagulation needed at therapeutic doses~* Absence of anticoagulation for more than 5 days after surgery~* Coagulopathy (not related to Disseminated intravascular coagulation syndrome)~* Thrombocytopenia~* Hemorrhagic diathesis~* Lower limb soft tissue infection~* Ankle-brachial index \< 0.6~  * Major surgery - intervention under endotracheal anesthesia with duration of more than 60 min.~    * In accordance with a standard stratification system, high risk of VTE group includes patients over 60 years old after major surgery and patients 40-60 years old with additional risk factors after major surgery.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (SCD + GCS + LMWH) (Type: EXPERIMENTAL): SCD: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.~GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
- Control group (GCS + LMWH) (Type: ACTIVE_COMPARATOR): GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Patient is greater than or equal to 18 and less than or equal to 78 years of age on the day of signing the consent~* Patient has Hb1Ac greater than or equal to 7.5% and is appropriate for oral therapy~* Patient has not been on any antihyperglycemic agent (AHA) in the last 4 months~* Patient is a male, or a female who is unlikely to conceive~Exclusion Criteria:~* Patient has type 1 diabetes mellitus or history of ketoacidosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: drug
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese men and women aged 20 years or older,~* Patients diagnosed as having Neovascular glaucoma (NVG) with neovascularization in the anterior segment (both iris and anterior chamber angle),~* Patients with Intraocular pressure (IOP) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization.~Exclusion Criteria:~* Patients with angle-closure due to conditions other than Neovascular glaucoma~* Patients with a known or suspected ocular or peri-ocular infection,~* Patients with severe intraocular inflammation in the study eye,~* Women who are pregnant, suspected of being pregnant or lactating,~* Patients with known allergy to aflibercept.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept (Type: EXPERIMENTAL): Aflibercept 2 mg Intravitreal (IVT) injection group
- Sham Injection (Type: SHAM_COMPARATOR): Sham injection group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: See General Eligibility Criteria~PATIENT CHARACTERISTICS: See General Eligibility Criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Faslodex in McCune-Albright Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females less than or equal to 10 years of age (prior to 11th birthday)~* Diagnosis of MAS~* PPP associated with MAS~Exclusion Criteria:~* Received any prior treatment for PPP associated with MAS with fulvestrant~* Abnormal platelet count or liver function tests~* Bleeding disorders~* Long term anticoagulation therapy~* Known hypersensitivity to any component of the study drug

- Gender: FEMALE
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Fulvestrant (Type: EXPERIMENTAL): Participants will receive intramuscular injection of fulvestrant 2 mg/kg or 4 mg/kg (First 10 participants will be dosed at 2 mg/kg then increased to 4 mg/kg. All subsequent participants will be dosed at 4 mg/kg) into the buttock or thigh monthly for 12 months or until the participant demonstrates lack of efficacy based upon one or more of the primary endpoints or experiences a serious drug-related toxicity requiring treatment discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is able to provide written informed consent before beginning any study related procedures~* Patient has a documented clinical diagnosis of major depressive disorder~* Patient is able to understand and comply with the requirements of the study, as judged by a study investigator~Exclusion Criteria:~* Patients with a history of non-compliance as judged by the study investigator~* Patients with a known lack of response to previous treatment with quetiapine~* Patients who have participated in a clinical trial within 4 weeks of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Measurable Disease~* Eastern Cooperative Oncology Group (ECOG) 0 or 1~* Lab / imaging requirements~* Neg for Human Immunodeficiency Virus (HIV), Hepatitis B (HepB), C~* Men and Women \> 18 years (16 were allowable)~* Prior therapy restriction (adjuvant only)~Exclusion:~* Pregnant / nursing~* Inadequate contraception~* Brain metastasis~* Primary ocular or mucosal melanoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Ipilimumab and Dacarbazine (Type: EXPERIMENTAL): In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
- Arm B: Placebo and Dacarbazine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete